A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

Running, not enrolling · Phase 3

Conditions studied: Recessive Dystrophic Epidermolysis Bullosa

In brief

The purpose of this study is to determine whether administration of FCX-007 in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Recessive Dystrophic Epidermolysis Bullosa. Funding Source - FDA OOPD

Key facts

Study ID

NCT04213261

Run by

Castle Creek Biosciences, LLC.

People needed

6

Starts

2020-06-09

Expected to finish

2037-07-01

Last updated by the study team

2026-03-18

Who can join

Age: 2 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Stanford University — Stanford, California, United States
• Children's Hospital Colorado — Aurora, Colorado, United States
• Solutions Through Advanced Research, Inc. — Jacksonville, Florida, United States
• Mayo Clinic — Rochester, Minnesota, United States
• Dell Children's Medical Group — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.